CNBC’s Angelica Peebles joins ‘Fast Money’ to report on Bristol Myers Squibb’s stock rise following FDA approval of Cobenfy for treating schizophrenia in adults.
Share
CNBC’s Angelica Peebles joins ‘Fast Money’ to report on Bristol Myers Squibb’s stock rise following FDA approval of Cobenfy for treating schizophrenia in adults.